Kirby Corporation's power generation segment, fueled by AI and data center demand, posted a 45% year-on-year revenue growth in Q1 2026 and is projected to contribute 45-55% of total revenues. Despite supply constraints affecting margins, the company's diversified revenue and marine transportation outlook provide resilience. Management forecasts a 5-15% increase in earnings per share for 2026, with consensus estimates at $7.01, indicating strong fundamentals and potential to exceed expectations.
Kazia Therapeutics is progressing its main cancer drug candidate, paxalisib, into Phase 2 trials for colorectal cancer and planning a new breast cancer study. The company recently raised $40 million to support these developments and maintains a stron...
Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa with a new price target of $18.50 following a major licensing deal with GSK. The agreement grants GSK exclusive rights to commercialize HCM's experimental cancer therapy ...
Duluth Holdings reported a strong Q2 earnings per share (EPS) of $0.50, far exceeding the consensus estimate of -$0.01, largely due to $0.44 per share from tariff refunds. Revenue reached $121.39 million, beating estimates but declining from the prev...
Estée Lauder Companies recently appointed new brand leaders, signaling strategic shifts in its competitive beauty market. An insider executive sold 7,766 shares worth over $802,000, leaving no remaining holdings. The company shows a high P/E ratio of...
HUTCHMED's shares surged 17.77% after announcing a major licensing deal with GSK for its preclinical cancer drug HMPL-A830. GSK gets exclusive rights outside Greater China, paying $110 million upfront plus up to $1.295 billion in milestone payments. ...
